Organigram FY2025 EPS Decreased by Alliance Global Partners

Key Points

• Alliance Global Partners has lowered its FY2025 earnings per share estimate for Organigram to $0.09, down from $0.12, while the consensus estimate remains at $0.16.
• Organigram's shares recently traded down 0.9% to C$2.12, with a notable debt-to-equity ratio of 3.07 and a current ratio of 3.36.
• The company has a market cap of C$261.91 million and has experienced a 12-month stock price range from C$1.22 to C$2.84.

Organigram Holdings Inc. (TSE:OGI - Free Report) - Alliance Global Partners dropped their FY2025 earnings per share (EPS) estimates for Organigram in a research report issued to clients and investors on Wednesday, August 13th. Alliance Global Partners analyst A. Grey now expects that the company will post earnings per share of $0.09 for the year, down from their previous forecast of $0.12. The consensus estimate for Organigram's current full-year earnings is $0.16 per share. Alliance Global Partners also issued estimates for Organigram's Q1 2026 earnings at ($0.03) EPS.

Organigram Price Performance

OGI traded up C$0.11 during trading on Friday, hitting C$2.12. The company's stock had a trading volume of 107,458 shares, compared to its average volume of 174,417. The company has a current ratio of 3.36, a quick ratio of 2.62 and a debt-to-equity ratio of 3.07. Organigram has a twelve month low of C$1.22 and a twelve month high of C$2.84. The business's fifty day simple moving average is C$1.96 and its 200 day simple moving average is C$1.77. The firm has a market capitalization of C$261.91 million, a price-to-earnings ratio of -4.48, a P/E/G ratio of 0.42 and a beta of 1.13.

About Organigram

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.